171 related articles for article (PubMed ID: 7640219)
21. Expression of ras oncogene p21 protein in normal and neoplastic ovarian tissues: correlation with histopathologic features and receptors for estrogen, progesterone, and epidermal growth factor.
Scambia G; Catozzi L; Panici PB; Ferrandina G; Coronetta F; Barozzi R; Baiocchi G; Uccelli L; Piffanelli A; Mancuso S
Am J Obstet Gynecol; 1993 Jan; 168(1 Pt 1):71-8. PubMed ID: 8420353
[TBL] [Abstract][Full Text] [Related]
22. Oestrogen and progesterone receptor content as a prognostic factor in advanced epithelial ovarian carcinoma.
Sevelda P; Denison U; Schemper M; Spona J; Vavra N; Salzer H
Br J Obstet Gynaecol; 1990 Aug; 97(8):706-12. PubMed ID: 2400748
[TBL] [Abstract][Full Text] [Related]
23. Expression of epidermal growth factor receptor in breast carcinoma.
Lewis S; Locker A; Todd JH; Bell JA; Nicholson R; Elston CW; Blamey RW; Ellis IO
J Clin Pathol; 1990 May; 43(5):385-9. PubMed ID: 2370306
[TBL] [Abstract][Full Text] [Related]
24. Epidermal growth factor receptors in human breast cancer: a plea for standardisation of assay methodology.
Koenders PG; Faverly D; Beex LV; Bruggink ED; Kienhuis CB; Benraad TJ
Eur J Cancer; 1992; 28(2-3):693-7. PubMed ID: 1591096
[TBL] [Abstract][Full Text] [Related]
25. Epidermal growth factor receptor and oestrogen receptors in the non-malignant part of the cancerous breast.
Barker S; Panahy C; Puddefoot JR; Goode AW; Vinson GP
Br J Cancer; 1989 Nov; 60(5):673-7. PubMed ID: 2803944
[TBL] [Abstract][Full Text] [Related]
26. Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers.
Yue Y; Astvatsaturyan K; Cui X; Zhang X; Fraass B; Bose S
PLoS One; 2016; 11(3):e0149661. PubMed ID: 26930401
[TBL] [Abstract][Full Text] [Related]
27. Progesterone receptor status is a significant prognostic variable of progression-free survival in advanced epithelial ovarian cancer.
Hempling RE; Piver MS; Eltabbakh GH; Recio FO
Am J Clin Oncol; 1998 Oct; 21(5):447-51. PubMed ID: 9781597
[TBL] [Abstract][Full Text] [Related]
28. Discordant human epidermal growth factor receptor 2 and hormone receptor status in primary and metastatic breast cancer and response to trastuzumab.
Chang HJ; Han SW; Oh DY; Im SA; Jeon YK; Park IA; Han W; Noh DY; Bang YJ; Kim TY
Jpn J Clin Oncol; 2011 May; 41(5):593-9. PubMed ID: 21406492
[TBL] [Abstract][Full Text] [Related]
29. The variation and clinical significance of hormone receptors and Her-2 status from primary to metastatic lesions in breast cancer patients.
Zhu YY; Si W; Ji TF; Guo XQ; Hu Y; Yang JL
Tumour Biol; 2016 Jun; 37(6):7675-84. PubMed ID: 26687919
[TBL] [Abstract][Full Text] [Related]
30. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
[TBL] [Abstract][Full Text] [Related]
31. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
[TBL] [Abstract][Full Text] [Related]
32. Expression of metastasis-related nm23-H1 and nm23-H2 genes in ovarian carcinomas: correlation with clinicopathology, EGFR, c-erbB-2, and c-erbB-3 genes, and sex steroid receptor expression.
Mandai M; Konishi I; Koshiyama M; Mori T; Arao S; Tashiro H; Okamura H; Nomura H; Hiai H; Fukumoto M
Cancer Res; 1994 Apr; 54(7):1825-30. PubMed ID: 7907945
[TBL] [Abstract][Full Text] [Related]
33. Steroid receptor content in human ovarian tumors: survival of patients with ovarian carcinoma related to steroid receptor content.
Iversen OE; Skaarland E; Utaaker E
Gynecol Oncol; 1986 Jan; 23(1):65-76. PubMed ID: 3943754
[TBL] [Abstract][Full Text] [Related]
34. The combined endocrine receptor in breast cancer, a novel approach to traditional hormone receptor interpretation and a better discriminator of outcome than ER and PR alone.
Campbell EJ; Tesson M; Doogan F; Mohammed ZMA; Mallon E; Edwards J
Br J Cancer; 2016 Oct; 115(8):967-973. PubMed ID: 27657341
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers.
Pichon MF; Broet P; Magdelenat H; Delarue JC; Spyratos F; Basuyau JP; Saez S; Rallet A; Courriere P; Millon R; Asselain B
Br J Cancer; 1996 Jun; 73(12):1545-51. PubMed ID: 8664127
[TBL] [Abstract][Full Text] [Related]
36. The clinicopathological characteristics of 'triple-negative' epithelial ovarian cancer.
Liu N; Wang X; Sheng X
J Clin Pathol; 2010 Mar; 63(3):240-3. PubMed ID: 20203223
[TBL] [Abstract][Full Text] [Related]
37. Epidermal growth factor receptor in human breast cancers: correlation with estrogen and progesterone receptors.
Delarue JC; Friedman S; Mouriesse H; May-Levin F; Sancho-Garnier H; Contesso G
Breast Cancer Res Treat; 1988 May; 11(2):173-8. PubMed ID: 3401606
[TBL] [Abstract][Full Text] [Related]
38. Epidermal growth factor receptor in breast cancer. Comparison with non malignant breast tissue.
Dittadi R; Donisi PM; Brazzale A; Cappellozza L; Bruscagnin G; Gion M
Br J Cancer; 1993 Jan; 67(1):7-9. PubMed ID: 8427782
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of estrogen and progesterone receptors in epithelial ovarian cancer.
Rose PG; Reale FR; Longcope C; Hunter RE
Obstet Gynecol; 1990 Aug; 76(2):258-63. PubMed ID: 2371031
[TBL] [Abstract][Full Text] [Related]
40. Effect of recombinant human interferon-alpha 2b on receptors for steroid hormones and epidermal growth factor in patients with endometrial cancer.
Scambia G; Panici PB; Battaglia F; Ferrandina G; Baiocchi G; Gallo A; Sica G; Mancuso S
Eur J Cancer; 1991; 27(1):51-3. PubMed ID: 1826442
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
